A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

Tadahiro Shoji,Eriko Takatori,Hideo Omi,Masahiro Kagabu,Tatsuya Honda,Masayuki Futagami,Yoshihito Yokoyama,Michiko Kaiho,Hideki Tokunaga,Takeo Otsuki,Tadao Takano,Nobuo Yaegashi,Takanobu Kojimahara,Tsuyoshi Ohta,Satoru Nagase,Shu Soeda,Takafumi Watanebe,Hiroshi Nishiyama,Toru Sugiyama

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

2017

Tadahiro Shoji
Eriko Takatori
Hideo Omi
Masahiro Kagabu
Tatsuya Honda
Masayuki Futagami
Yoshihito Yokoyama
Michiko Kaiho
Hideki Tokunaga
Takeo Otsuki
Tadao Takano
Nobuo Yaegashi
Takanobu Kojimahara
Tsuyoshi Ohta
Satoru Nagase
Shu Soeda
Takafumi Watanebe
Hiroshi Nishiyama
Toru Sugiyama

Purpose We report a phase II clinical study of the combination of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in platinum- and taxane-resistant recurrent ovarian cancer, based on the recommended doses determined in a phase I trial.

Keywords:

Pegylated Liposomal Doxorubicin
Oncology
Cancer
Internal medicine
Phases of clinical research
Pharmacology
Chemotherapy
Recurrent Ovarian Cancer
Irinotecan
Medicine
Surgery
Gastroenterology
Nausea
Neutropenia
Adverse effect
Combination therapy
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations